UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

(Mark  One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended December 31, 2006

                                       OR

[ ]  TRANSITION REPORT PURUSANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

                        Commission file number 33-19598-D

                                    VYTA CORP
                                    ---------
        (Exact name of small business issuer as specified in its charter)

                Nevada                                      84-0992908
                ------                                      ----------
  (State or other jurisdiction of                        (I.R.S. employer
   incorporation or organization)                    identification  number)

                           370 17th Street, Suite 3640
                             Denver, Colorado 80202
                    (Address of principal executive offices)

         Issuer's telephone number, including area code:  (303) 592-1010

Check  whether  the  issuer  (1)  has  filed all reports required to be filed by
Section 13(a) or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports),  and  (2) has been subject to such filing requirements for the past 90
days.     Yes  X    No
              ---      ---

Indicate  by check mark whether the registrant is a shell company (as defined in
Rule  12b-2  of  the  Exchange  Act).     Yes      No  X
                                              ---     ---

State the number of shares outstanding of each of the issuer's classes of common
equity,  as  of  the  latest  practicable  date:

As of February 19, 2007 there were 22,643,512 shares of the registrant's sole
class of common shares outstanding.

Transitional  Small  Business  Disclosure  Format     Yes      No  X
                                                          ---     ---


<PAGE>
<TABLE>
<CAPTION>
PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements (Unaudited)                                       Page
                                                                                ----
<S>                                                                             <C>
         Condensed Consolidated Balance Sheet - December 31, 2006               F-1

         Condensed Consolidated Statements of Operations  -
              Three and Six months ended December 31, 2006 and 2005             F-2

         Condensed Consolidated Statements of Comprehensive
              Loss - Three and Six months ended December 31, 2006 and 2005      F-3

         Condensed Consolidated Statement of Changes in Shareholders'
              Equity -Six months ended December 31, 2006                        F-4

         Condensed Consolidated Statements of Cash Flows -
              Six months ended December 31, 2006 and 2005                       F-5

         Notes to Condensed Consolidated Financial Statements                   F-7

Item 2.  Management's Discussion and Analysis                                   1

Item 3.  Controls and Procedures                                                3

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings -Not Applicable                                      4

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds            4
              - Not Applicable

Item 3.  Defaults Upon Senior Securities - Not Applicable                       4

Item 4.  Submission of Matters to a Vote of Security Holders - Not Applicable   4

Item 5.  Other Information - Not Applicable                                     4

Item 6.  Exhibits                                                               5

SIGNATURES                                                                      6
</TABLE>


<PAGE>
<TABLE>
<CAPTION>
                         PART I - FINANCIAL INFORMATION


ITEM 1.  FINANCIAL STATEMENTS

                            VYTA CORP AND SUBSIDIARIES
                       Condensed Consolidated Balance Sheet
                                 December 31, 2006
                                    (Unaudited)

                                       Assets
                                       ------

<S>                                                                  <C>
Current assets:
  Cash and cash equivalents                                          $     42,438
  Prepaid expenses                                                        202,401
                                                                     -------------
    Total current assets                                                  244,839
                                                                     -------------

Property and equipment:
  Office equipment and furniture                                           67,108
  Less accumulated depreciation                                           (58,977)
                                                                     -------------
                                                                            8,131
                                                                     -------------

Other assets:
  Deposits and other                                                       19,509
  Notes receivable, equity investee (Note 2)                            1,600,394
  Investment in equity investee(Note 3)                                   242,125
                                                                     -------------
                                                                        1,862,028
                                                                     -------------

       Total assets                                                  $  2,114,998
                                                                     =============

                      Liabilities and Shareholders' Equity
                      ------------------------------------

Current liabilities:
  Accounts payable                                                   $    125,470
  Advances payable, related parties (Note 4)                              582,823
  Accrued liabilities                                                       7,063
                                                                     -------------
    Total liabilities  (all current)                                      715,356
                                                                     -------------

Commitments and contingencies (Notes 4 and 5)

Shareholders' equity:
  Preferred stock; $0.0001 par value; 5,000,000 shares authorized;
     none issued and outstanding
  Common stock; $0.0001 par value; 200,000,000 shares authorized;
     22,643,512 shares issued and outstanding                               2,264
  Additional paid-in capital                                           28,390,883
  Accumulated other comprehensive income                                  130,530
  Accumulated deficit                                                 (27,124,035)
                                                                     -------------
      Total shareholders' equity                                        1,399,642
                                                                     -------------

        Total liabilities and shareholders' equity                   $  2,114,998
                                                                     =============
</TABLE>

See notes to condensed consolidated financial statements.


                                      F - 1
<PAGE>
<TABLE>
<CAPTION>
                                  VYTA CORP AND SUBSIDIARIES
                      Condensed Consolidated Statements of Operations
                                        (Unaudited)

                                             Three Months Ended        Six Months Ended
                                                December 31,              December 31,
                                        -------------------------  ------------------------
                                            2006         2005         2006         2005
                                        ------------  -----------  -----------  -----------
<S>                                     <C>           <C>          <C>          <C>
Revenues                                $         -            -            -            -
                                        ------------  -----------  -----------  -----------

General and administrative expenses        (271,352)    (216,188)    (546,766)    (441,027)
                                        ------------  -----------  -----------  -----------

Loss from operations                       (271,352)    (216,188)    (546,766)    (441,027)
                                        ------------  -----------  -----------  -----------

Other income (expense):
  Other income                                    -            -            -       28,585
  Interest income                                12        4,419           12        8,350
  Equity losses of equity investees
    (Note 3)                               (272,583)    (129,747)    (540,141)    (389,654)
  Loss on revaluation of derivative
   warrant liability                              -       (4,158)           -       (4,158)
  Interest expense                                -            -            -     (235,131)
  Interest expense, related party                 -            -            -         (219)
                                        ------------  -----------  -----------  -----------
                                           (272,571)    (129,486)    (540,129)    (592,227)
                                        ------------  -----------  -----------  -----------

Net loss                                $  (543,923)    (345,674)  (1,086,895)  (1,033,254)
                                        ============  ===========  ===========  ===========

Net loss per share, basic and diluted
  (Note 1)                              $     (0.02)       (0.05)       (0.05)       (0.16)
                                        ============  ===========  ===========  ===========

Weighted average number of common
  shares outstanding (Note 1)            22,643,512    6,855,418   22,643,512    6,327,884
                                        ============  ===========  ===========  ===========
</TABLE>

     See notes to condensed consolidated financial statements.


                                      F - 2
<PAGE>
<TABLE>
<CAPTION>
                                 VYTA CORP AND SUBSIDIARIES
                  Condensed Consolidated Statements of Comprehensive Loss
                                        (Unaudited)

                                         Three Months Ended           Six Months Ended
                                            December 31,                 December 31,
                                     --------------------------  --------------------------
                                         2006          2005          2006          2005
                                     ------------  ------------  ------------  ------------
<S>                                  <C>           <C>           <C>           <C>
Net loss                             $  (543,923)     (345,674)   (1,086,895)   (1,033,254)

Change in unrealized gain (loss) on
  securities                                 136             -           171          ( 14)
                                     ------------  ------------  ------------  ------------

Comprehensive loss                   $  (543,787)     (345,674)   (1,086,724)   (1,033,268)
                                     ============  ============  ============  ============
</TABLE>

     See notes to condensed consolidated financial statements.


                                      F - 3
<PAGE>
<TABLE>
<CAPTION>
                                             VYTA CORP AND SUBSIDIARIES
                         Condensed Consolidated Statement of Changes in Shareholders' Equity
                                         Six Months Ended December 31, 2006
                                                     (Unaudited)

                             Common stock           Additional      Accumulated other                     Total
                        -----------------------       paid-in        comprehensive    Accumulated     shareholders'
                          Shares      Amount          capital            income         deficit          equity
                        ----------  -----------  ------------------  --------------  --------------  ---------------
<S>                     <C>         <C>          <C>                 <C>             <C>             <C>
Balances, July 1, 2006  22,643,512  $     2,264  $       28,390,883  $      130,359  $ (26,037,140)  $    2,486,366

Net loss                         -            -                   -               -     (1,086,895)      (1,086,895)

Change in unrealized
  gain on securities             -            -                   -             171              -              171
                        ----------  -----------  ------------------  --------------  --------------  ---------------
Balances,
  December 31, 2006     22,643,512        2,264          28,390,883         130,530    (27,124,035)       1,399,642
                        ==========  ===========  ==================  ==============  ==============  ===============
</TABLE>

See notes to condensed consolidated financial statements.


                                      F - 4
<PAGE>
<TABLE>
<CAPTION>
                                VYTA CORP AND SUBSIDIARIES
                      Condensed Consolidated Statements of Cash Flows
                                        (Unaudited)

                                                                     Six Months Ended
                                                                       December 31,
                                                                ---------------------------
                                                                    2006           2005
                                                                -------------  ------------
<S>                                                             <C>            <C>
Cash flows from operating activities:
  Net loss                                                      $ (1,086,895)   (1,033,254)
                                                                -------------  ------------
  Adjustments to reconcile net loss to net cash used
    in operating activities:
    Amortization expense                                             234,411        45,370
    Depreciation expense                                               2,694         2,853
    Equity losses of equity investees                                540,141       389,654
    Amortization of discounts on notes payable                             -       213,760
    Loss on revaluation of derivative warrant
      liability                                                            -         4,158
    Changes in operating assets and liabilities:
      Decrease in interest receivable                                      -         2,894
      Decrease in prepaid expenses                                    15,967           960
      Increase (decrease) in accounts payable and accrued
        liabilities                                                   54,879       (53,774)
                                                                -------------  ------------
  Total adjustments                                                  848,092       605,875
                                                                -------------  ------------

        Net cash used in operating activities                       (238,803)     (427,379)
                                                                -------------  ------------

Cash flows from investing activities:
    Increase in notes receivable                                    (387,118)     (400,000)
    Payment on note receivable                                             -        89,119
    Investment in joint venture                                            -      (500,000)
                                                                -------------  ------------
        Net cash used in investing activities                       (387,118)     (810,881)
                                                                -------------  ------------

Cash flows from financing activities:
    Exercise of warrants, and common stock and warrants issued
      for cash                                                             -     2,070,500
    Proceeds to be applied to preferred stock
      purchase (Note 4)                                              476,000       200,000
    Payment of notes payable                                               -      (960,663)
    Proceeds from issuance of notes payable and common stock               -       150,000
                                                                -------------  ------------
        Net cash provided by financing activities                    476,000     1,459,837
                                                                -------------  ------------

Net (decrease) increase in cash and cash equivalents                (149,921)      221,577

Cash and cash equivalents, beginning                                 192,359        25,835
                                                                -------------  ------------

Cash and cash equivalents, ending                               $     42,438       247,412
                                                                =============  ============
</TABLE>

                                   (Continued)


                                      F - 5
<PAGE>
<TABLE>
<CAPTION>
                             VYTA CORP AND SUBSIDIARIES
                   Condensed Consolidated Statements of Cash Flows
                                     (Unaudited)
                                      Continued

                                                                  Six Months Ended
                                                                     December 31,
                                                               ----------------------
                                                                  2006        2005
                                                               -----------  ---------
<S>                                                            <C>          <C>
Supplemental disclosure of cash flow information:
  Cash paid for interest                                       $         -      1,069
                                                               ===========  =========

Supplemental disclosure of non-cash investing and financing
  activities:
    Issuance of common stock in connection with notes payable  $         -    117,886
                                                               ===========  =========
    Issuance of common stock in exchange for accrued
      commissions                                              $         -     90,000
                                                               ===========  =========
    Advances receivable applied to equity investment           $         -    405,000
                                                               ===========  =========
    Equity investment acquired in exchange for note payable    $         -    595,000
                                                               ===========  =========
    Liability recorded for offering costs of common stock
      issuance                                                 $         -    800,000
                                                               ===========  =========
    Forgiveness of accrued payroll owed to
      officer/shareholder                                      $         -      8,750
                                                               ===========  =========
    Issuance of common stock in exchange for receivable        $         -      2,000
                                                               ===========  =========
</TABLE>

See notes to condensed consolidated financial statements.


                                      F - 6
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


1.     BASIS  OF  PRESENTATION,  MANAGEMENT'S  PLANS  AND SUMMARY OF SIGNIFICANT
       ACCOUNTING  POLICIES:

Presentation of Interim Information:

The  accompanying  condensed  consolidated  financial  statements  include  the
accounts  of  Vyta  Corp,  a  Nevada corporation (the Company), its wholly-owned
subsidiaries,  NanoPierce Connection Systems, Inc., a Nevada corporation (NCOS),
and  ExypnoTech,  LLC  (ET  LLC).  All  significant  intercompany  accounts  and
transactions  have  been  eliminated  in  consolidation.  NCOS and ET LLC had no
revenues  or  operations in 2006 and 2005. The Company has two investments which
are  accounted  for  using  the equity method of accounting. These equity method
investments  consist  of  ExypnoTech, GmbH (EPT) and BioAgra, LLC (BioAgra)(Note
3).  The  Company's  equity  investees,  EPT  and  BioAgra,  operate  in  two
segments,  the  RFID  industry  and  the  animal  feed  industry,  respectively.

In  the  opinion  of  the  management of the Company, the accompanying unaudited
condensed  consolidated  financial  statements include all material adjustments,
including  all normal and recurring adjustments, considered necessary to present
fairly  the  financial  position  and  operating  results of the Company for the
periods  presented.  The  financial  statements  and  notes  are  presented  as
permitted by Form 10-QSB, and do not contain certain information included in the
Company's  Annual Report on Form 10-KSB for the fiscal year ended June 30, 2006.
It  is  management's opinion that when the interim financial statements are read
in  conjunction  with  the  June  30,  2006  Annual  Report  on Form 10-KSB, the
disclosures  are  adequate  to  make  the  information presented not misleading.
Interim results are not necessarily indicative of results for a full year or any
future  period.

Management's  Plans:

In the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30,
2006,  the  Report of the Independent Registered Public Accounting Firm includes
an  explanatory  paragraph  that describes substantial doubt about the Company's
ability  to  continue  as  a  going  concern.  The  Company's  interim financial
statements  for  the  six months ended December 31, 2006 have been prepared on a
going  concern  basis,  which  contemplates  the  realization  of assets and the
settlement of liabilities and commitments in the normal course of business.  The
Company  reported a net loss of $1,086,895 for the six months ended December 31,
2006,  and  an  accumulated deficit of $27,124,035 as of December 31, 2006.  The
Company  also  has  a  working  capital  deficiency at December 31, 2006 and the
Company  has  not  recognized  any  revenues  from  its  business  operations.


                                      F - 7
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


The  Company's  ability  to  continue as a going concern may be dependent on the
success  of  management's plans discussed below. The financial statements do not
contain  any  adjustments  relating  to the recoverability and classification of
assets  or the amounts and classification of liabilities that might be necessary
should  the  Company  be  unable to continue as a going concern. During the 2007
fiscal year, the Company intends to continue its efforts to assist BioAgra (Note
3)  with the continuing development of its sales, nationally and internationally
in  other  animal  feed  markets,  such  as the equine and the swine markets. In
addition, in January 2007 the Company signed a six-month Technology Agreement to
permit  a  prospective  licensee  the  opportunity  to  conduct  a market survey
relating  to  its  NCOS(TM)  technology.  Management believes that if the market
survey  is  favorable, the Technology Agreement may mature into a royalty paying
commercial  license,  the  terms  and  conditions of which are under negotiation
between  the  Company  and  the  perspective  licensee.

The  Company  also  intends  to raise funds to support operations of the Company
during  the  2007 fiscal year through a private offering of preferred stock, the
terms  of  which  are  being  negotiated.

Currently,  the  Company  does  not  have  a  revolving  loan agreement with any
financial institution, nor can the Company provide any assurance it will be able
to  enter  into  any  such  agreement  in  the future, or be able to raise funds
through  a  further  issuance  of  debt  or  equity  in  the  Company.

Deferred Consulting Costs:

In  June  2006,  the  Company  entered  into  a twelve-month consulting services
agreement  with  two  third  parties,  in  which  the  parties agreed to provide
lobbying and public relation services.  Compensation consisted of 200,000 shares
of  the  Company's  common  stock  with a market value of approximately $182,000
(based  on a closing market price of $0.91 per share at the date the transaction
was  entered  into)  and  a  warrant to purchase 500,000 shares of the Company's
common  stock,  with an exercise price of $0.91 per share and a term of 3 years.
The warrant was valued at $283,000 using the Black-Scholes pricing model method.
The deferred cost is being amortized on a straight-line basis as earned over the
twelve-month period from the date of the agreement.  During the six months ended
December  31,  2006,  $234,411  was  expensed.

In  June  2005,  the  Company  entered  into  a twelve-month consulting services
agreement  with  a third party, in which this party agreed to provide public and
investor  relation  services  and general business services for the twelve-month
term  of  the  agreement.  Compensation  consisted  of  1,000,000  shares of the
Company's  restricted  common stock with a market value of approximately $90,000
(based  on  the  closing  market  price  of  $0.09  per share at the date of the
transaction).  The  deferred  cost  was  amortized  on  a straight-line basis as
earned over the twelve-month period from the date of the agreement and therefore
has  been  fully-amortized.  During  the  six  months  ended  December 31, 2005,
$45,370  was  expensed.


                                      F - 8
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


Loss Per Share:

Basic  Earnings  Per  Share  (EPS)  excludes dilution.  Diluted EPS reflects the
potential  dilution  that  could occur if securities or other contracts to issue
common  stock  were  exercised or converted into common stock or resulted in the
issuance  of  common stock that then shared in the earnings of the entity.  Loss
per  share  of  common stock is computed based on the weighted average number of
common shares outstanding during the period.  Stock options and warrants are not
considered  in  the  calculation,  as  the impact of the potential common shares
(6,519,469  shares  at  December  31,  2006 and 1,926,877 shares at December 31,
2005) would be to decrease loss per share.  Therefore, diluted loss per share is
equivalent  to  basic  loss  per  share.

Stock-Based Compensation:

Beginning  July  1, 2006, the Company adopted the provisions of and accounts for
stock-based  compensation  in accordance with the Financial Accounting Standards
Board's  ("FASB")  Statement of Financial Accounting Standards No. 123 - revised
2004 ("SFAS 123R"), "Share-Based Payment", which replaced Statement of Financial
Accounting  Standards  No.  123("SFAS  123"),  "Accounting  for  Stock-Based
Compensation",  and  supersedes  APB  Opinion  No. 25 ("APB 25"), Accounting for
Stock Issued to Employees".  Under the fair value recognition provisions of this
statement,  stock-based compensation cost is measured at the grant date based on
the  fair  value  of  the  award and is recognized as expense on a straight-line
basis  over  the  requisite  service  period,  which is the vesting period.  The
Company  elected  the modified-prospective method, under which prior periods are
not  revised  for  comparative  purposes.  The valuation provisions of SFAS 123R
apply to new grants and to grants that were outstanding as of the effective date
and  are  subsequently  modified.  There  were no options granted during the six
months  ended  December  31, 2006 and 2005, and all options granted prior to the
adoption  of  SFAS  123R  and  outstanding  during  the  periods  presented were
fully-vested.

The  Company  has  two  stock  option  plans which permit the grant of shares to
attract,  retain  and  motivate  employees,  directors  and consultants of up to
625,000  shares of common stock.  Options are generally granted with an exercise
price equal to the Company's market price of its common stock on the date of the
grant  and  with  vesting  rates,  as determined by the Board of Directors.  All
options  outstanding  at July 1, 2006 and December 31, 2006 are fully-vested and
exercisable.  A summary of outstanding balances at July 1, 2006 and December 31,
2006  is  as  follows:

<TABLE>
<CAPTION>
                                     Weighted-   Weighted-
                                      average     average    Aggregate
                                      exercise   remaining   intrinsic
                            Options    price        life       value
                            -------------------------------------------
<S>                         <C>      <C>         <C>         <C>
     Outstanding at:

       July 1, 2006         398,127  $    22.00  4.61 years  $        0

       December 31, 2006    398,127  $    22.00     4 years  $        0
</TABLE>


                                      F - 9
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


Recently  Issued  Accounting  Standards:

In  September  2006,  the  FASB  issued SFAS No. 157, "Fair Value Measurements".
This  statement  defines  fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures about
fair  value  measurements.  This  statement  applies  under  other  accounting
pronouncements  that require or permit fair value measurements.  SFAS No. 157 is
effective  for  the  Company for its fiscal year beginning on July 1, 2008.  The
Company is currently assessing the impact the adoption of SFAS No. 157 will have
on  its  consolidated  financial  statements.

In  September  2006,  the  SEC issued Staff Accounting Bulletin (SAB) No. 108 in
order  to  eliminate  the diversity of practice surrounding how public companies
quantify  financial  statement  misstatements.  In  SAB  108,  the  SEC  staff
established  an  approach  that  requires  quantification of financial statement
misstatements based on the effects of the misstatements on each of the Company's
financial  statements  and the related financial statement disclosures.  SAB No.
108  is  effective for the Company for its current fiscal year.  The adoption of
SAB  No.  108  did  not  have  an impact on the Company's consolidated financial
statements.

2.     NOTES  RECEIVABLE  -  EQUITY  INVESTEE:

During  the  year  ended June 30, 2006, the Company loaned $1,726,827 to BioAgra
(Note  3)  in  exchange  for a secured, 7.5% promissory note with payments to be
made monthly starting October 31, 2006, through October 31, 2007. The funds were
loaned  to  facilitate  BioAgra's completion of its first production line and to
support  operations.  The  promissory note is collateralized by all of BioAgra's
assets.  Additionally,  the  promissory  note is to be paid in full prior to any
distributions  being  made  to  the members of the joint venture. During the six
months  ended  December  31,  2006,  the  note  was  reduced  by $513,551, which
represents  the  excess of the BioAgra losses recognized by the Company over the
adjusted  basis  of  the  Company's equity investment in BioAgra at December 31,
2006  (Note  3).

During  the  six  months  ended  December  31,  2006,  the  Company  advanced an
additional  $387,118  to  BioAgra  under  the same terms as the promissory note,
described above.  In January 2007, the Company advanced an additional $53,500 to
BioAgra  under  the  same  terms  as  the promissory note, described above.  The
Company  has  classified  these  notes  receivable  as non-current assets on the
balance sheet and is not accruing interest on these notes receivable as they are
currently  in  default  and  non-performing.  The  scheduled  payments under the
promissory  note  have  not  been  made.

3.     INVESTMENTS IN AFFILIATES:

Investment in EPT:

The  carrying  amount of the Company's investment in EPT is $242,125 at December
31,  2006,  and  is  adjusted  to recognize the Company's proportionate share of
EPT's  income  (loss)  each  period.


Unaudited  financial  information  of  EPT  as of December 31, 2006, and for the
three  and  six-month  periods  ended December 31, 2006 and 2005 are as follows:


                                     F - 10
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


<TABLE>
<CAPTION>
                                             December 31,
                                                 2006
                                             -------------
<S>                                          <C>
     Assets:
          Current assets(1)                  $     673,924
          Equipment                                 47,151
                                             -------------

       Total assets                          $     721,075
                                             =============

     Liabilities and members' equity:
         Current liabilities(2)              $     357,087
         Members' equity                           363,988
                                             -------------

     Total liabilities and members' equity   $     721,075
                                             =============
</TABLE>

     (1)  Current  assets  include  receivables  of  $641,722  due  from the 51%
          owner  of  EPT.
     (2)  Current  liabilities  include  a  payable  of  $29,473  due to the 51%
          owner  of  EPT.

<TABLE>
<CAPTION>
              Three Months   Three Months    Six Months     Six Months
                 Ended          Ended          Ended          Ended
              December 31,   December 31,   December 31,   December 31,
                  2006           2005           2006           2005
             --------------  -------------  -------------  -------------
<S>          <C>             <C>            <C>            <C>
Revenues(1)  $   1,271,198        645,460      1,839,740      1,045,196
Expenses(2)     (1,182,660)      (707,287)    (1,674,991)    (1,141,600)
             --------------  -------------  -------------  -------------
Net income
  (loss)     $      88,538        (61,827)       164,749        (96,404)
             ==============  =============  =============  =============
</TABLE>

     (1)  Revenues  for  the  six  months  ended  December  31,  2006  and  2005
          include  $1,839,740  and  $1,045,196,  respectively  ($1,271,198  and
          $645,460  for  the  three  months  ended  December  31, 2006 and 2005,
          respectively)  of  sales  to  the  51%  owner  of  EPT for each period
          presented.
     (2)  Expenses  for  the  six  months  ended  December  31,  2006  and  2005
          include $80,677 and $45,671, respectively ($42,399 and $37,756 for the
          three  months  ended  December  31,  2006  and  2005, respectively) of
          charges  paid  to  the  51%  owner  of  EPT for each period presented.

Investment in BioAgra:

On  August  15,  2005,  the  Company  entered  into  a  joint  venture with Xact
Resources,  a  privately-held  company.  The  Company  purchased  a  50%  equity
interest  in  the  joint  venture, BioAgra, for $905,000 in cash (which includes
$405,000  previously  advanced to Xact Resources as of June 30, 2005) and a note
payable  of  $595,000, which was paid in full on September 15, 2005.  BioAgra is
to  manufacture  and  sell  a  beta  glucan  product,  YBG-2000  also  known  as
AgraStimTM,  to  be  used  as  a  replacement  for  hormone  growth steroids and
antibiotics  in products such as poultry feed.  As of December 31, 2006, BioAgra
(a  development  stage  company) has completed construction of a production line
and  has  produced  and  shipped  product  in  limited  quantities.

The  terms of the joint venture provide for the Company to share in 50% of joint
venture  net income, if any, or net losses.  Net losses incurred by BioAgra have
exceeded  the  underlying  equity  attributed  to  BioAgra's other joint venture
investor.  As  a  result,  the  excess  of  the  losses  attributable


                                     F - 11
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


to  the  other  joint venture investor have been charged to the Company. BioAgra
incurred  a  net  loss  of  $620,867  for the six months ended December 31, 2006
($315,962  for  the three months ended December 31, 2006). At September 30, 2006
the carrying value of the Company's investment in BioAgra was $0. The losses for
the  three  months ended December 31, 2006 ($315,962) were applied to reduce the
value  of  the  note  receivable  from  BioAgra.

Unaudited  financial  information of BioAgra as of December 31, 2006 and for the
three  and  six  months  ended December 31, 2006, and the period from August 15,
2005  (inception)  through December 31, 2005 and the three months ended December
31,  2005,  is  as  follows:

<TABLE>
<CAPTION>
                                                  December 31, 2006
                                                 -------------------
<S>                                              <C>
     Assets:
          Current assets                         $          183,514
          Land, building and equipment, net(2)            2,859,259
          Other assets, net                                  93,123
                                                 -------------------

       Total assets                              $        3,135,896
                                                 ===================

     Liabilities and members' equity:
          Current liabilities(1)                 $        2,666,080
          Obligation under capital lease(2)                 983,367
                                                 -------------------

       Total liabilities                                  3,649,447

       Members' deficiency                                 (513,551)
                                                 -------------------

     Total liabilities and members' deficiency   $        3,135,896
                                                 ===================
</TABLE>

     (1)  Includes  $2,113,945  owed  to  the  Company.
     (2)  BioAgra  leases  land  and  a  building  under  a  ten-year  lease
          expiring  in  February 2015, which requires a monthly lease payment of
          $12,000.

<TABLE>
<CAPTION>
           Three Months   Three Months    Six Months     August 15,
              Ended          Ended          Ended       2005 through
           December 31,   December 31,   December 31,   December 31,
               2006           2005           2006           2005
          --------------  -------------  -------------  -------------
<S>       <C>             <C>            <C>            <C>
Revenues  $           -              -         31,642              -
Expenses       (315,962)      (198,902)      (652,509)      (684,832)
          --------------  -------------  -------------  -------------
Net loss  $    (315,962)      (198,902)      (620,867)      (684,832)
          ==============  =============  =============  =============
</TABLE>

4.     ADVANCES PAYABLE - RELATED PARTIES:

In  June  2006,  the  Company  received  an  advance  of  $100,000  from Arizcan
Properties,  Ltd. (Arizcan).  During the six months ended December 31, 2006, the
Company  received  additional advances of $476,000 from Arizcan.  Total advances
at  December  31, 2006 are $576,000. The advances are to be applied to an equity
placement that the Company and Arizcan have not yet finalized. The proceeds were
used  to  fund  the  Company's  operations.


                                     F - 12
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


During  the  six months ended December 31, 2006, the Company received an advance
of  $6,823  from Paul H. Metzinger, the President and Chief Executive Officer of
the  Company.

5.     COMMITMENTS AND CONTINGENCIES:

LITIGATION:

Depository  Trust  Suit:

In  May  2004,  the Company filed suit against the Depository Trust and Clearing
Corporation  ("DTCC"),  the  Depository  Trust Company ("DTC"), and the National
Securities  Clearing  Corporation ("NSCC") in the Second Judicial District Court
of the County of Washoe, State of Nevada. The suit alleges multiple claims under
the  Nevada  Revised  Statutes  90.570, 90.580, 90.660 and 598A.060 and on other
legal  bases.  The complaint alleges, among other things, that the DTCC, DTC and
NSCC  acted in concert to operate the "Stock Borrow Program," originally created
to  address  short  term delivery failures by sellers of securities in the stock
market. According to the complaint, the DTCC, NSCC and DTC conspired to maintain
significant  open  fail deliver positions of millions of shares of the Company's
common  stock  for extended periods of time by using the Stock Borrow Program to
cover these open and unsettled positions. The Company was seeking damages in the
amount  of  $25,000,000 and treble damages. Responsive pleadings have been filed
by  the  defendants.  In  April  2005, the court granted a motion to dismiss the
lawsuit. The Company filed an appeal to the Supreme Court of the State of Nevada
to  overturn  the motion to dismiss the lawsuit. Oral argument on the appeal was
presented before the Nevada State Supreme Court in February 2007. The Company is
awaiting  a  decision  on  the  appeal,  at  this  time.

Financing  Agreement  Suit:

In  connection  with  a  financing  obtained  in October 2000, the Company filed
various actions in the United States District Court for the District of Colorado
against,  among others, Harvest Court, LLC, Southridge Capital Investments, LLC,
Daniel  Pickett,  Patricia  Singer and Thomson Kernaghan, Ltd. for violations of
federal  and  state  securities laws, conspiracy, aiding and abetting and common
law  fraud  among  other  claims.  As a result of various procedural rulings, in
January  2002,  the  United  States  District Court for the District of Colorado
transferred  the  case  to  the  United  States  District Court for the Southern
District  of  New  York,  New  York City, New York.  In this litigation, Harvest
Court,  LLC  filed  counterclaims  against  the Company and certain officers and
former  board  members  of the Company, and a number of unrelated third parties.
The  counterclaims  allege violations of federal securities laws and other laws.
Harvest Court, LLC is seeking various forms of relief including compensatory and
punitive  damages.  Responsive  pleadings  have been filed and the litigation is
currently  in  the  discovery  stage.

In  May  2001,  Harvest Court, LLC filed suit against the Company in the Supreme
Court  of  the State of New York, County of New York.  The suit alleges that the
Company  breached  an  October 20, 2000 Stock Purchase Agreement, by not issuing
7,418,895  free  trading shares of the Company's common stock in connection with
the  reset provisions of the Purchase Agreement due on the second reset date and
approximately  4,500,225  shares  due  in  connection with the third reset date.
Harvest  Court,  LLC  is  seeking  the delivery of such shares or damages in the
alternative.  In  August  2001,  the  Supreme  Court  of


                                     F - 13
<PAGE>
                           VYTA CORP AND SUBSIDIARIES
            Notes to the Condensed Consolidated Financial Statements
                   Six Months Ended December 31, 2006 and 2005
                                   (Unaudited)


the  State  of  New  York,  County  of  New York issued a preliminary injunction
ordering  the  Company  to  reserve and not transfer the shares allegedly due to
Harvest  Court,  LLC.  The Company has filed counterclaims seeking various forms
of  relief  against  Harvest  Court,  LLC.

The Company intends to vigorously prosecute this litigation and does not believe
the  outcome  of  this  litigation  will  have  a material adverse effect on the
financial  condition,  results  of  operations  or  liquidity  of  the  Company.
However, it is too early at this time to determine the ultimate outcome of these
matters.


                                     F - 14
<PAGE>
ITEM  2.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS

     Certain  statements  contained in this Form 10-QSB contain "forward-looking
statements"  within  the meaning of the Private Securities Litigation Reform Act
of  1995  and involve risks and uncertainties that could cause actual results to
differ  materially  from  the  results,  financial  or  otherwise,  or  other
expectations  described in such forward-looking statements.  Any forward-looking
statement  or statements speak only as of the date on which such statements were
made,  and  the  Company  undertakes no obligation to update any forward-looking
statement  to  reflect  events  or  circumstances  after  the date on which such
statements  are  made  or  reflect  the  occurrence  of  unanticipated  events.
Therefore, forward-looking statements should not be relied upon as prediction of
actual  future  results.

     The independent registered public accounting firm's report on the Company's
consolidated financial statements as of June 30, 2006, and for each of the years
in  the  two-year  period  then  ended,  includes  a "going concern" explanatory
paragraph,  that  describes  substantial  doubt  about  the Company's ability to
continue  as  a  going  concern.  Management's  plans  in  regard to the factors
prompting  the  explanatory  paragraph are discussed below and also in Note 1 to
the  unaudited  quarterly  financial  statements.

RESULTS  OF  OPERATIONS

     The  Company  had no revenues during the six months ended December 31, 2006
and  2005.

     Total  general  and  administrative  expenses  during  the six months ended
December  31,  2006  were $546,766 compared to $441,027 for the six months ended
December 31, 2005 ($271,352 and $216,188 for the three months ended December 31,
2006  and  2005, respectively). The six-month increase of $105,739, is primarily
attributable  as  set  forth  on  the  table  below.

<TABLE>
<CAPTION>
           General and       $ Increase or
     Administrative Expense   (Decrease)
     ----------------------  -------------
<S>                          <C>
     Consulting expenses     $    204,596
     Accounting expenses           20,768
     Commission fees              (68,210)
     Rent expense                 (24,868)
     Public relations             (23,339)
</TABLE>

     The  Company  recognized  $8,350  in  interest income during the six months
ended  December  31,  2005  ($4,419  during  the three months ended December 31,
2005).  During  the  six  months ended December 31, 2005, the Company recognized
$28,585  in  other  income,  which  represented  a gain on the extinguishment of
certain  liabilities.

     No  interest  expense was recorded during the six months ended December 31,
2006,  as  no  debt  was  outstanding during the period.  The Company recognized
interest  expense of $235,350 for the six months ended December 31, 2005 ($0 for
the three months ended December 31, 2005).  Of the $235,350 in interest expense,
$219  represented related party interest. The remaining $235,131 was incurred in
connection  with the issuance of promissory notes, which were discounted for the
fair  value  of  warrants  included  with  debt  at  the  time of issuance.  The
resulting  discounts  ($213,760)  were  amortized  over


                                        1
<PAGE>
the term of the promissory notes.  The promissory notes were paid in full during
the  three  months ended September 30, 2005, and at that time the discounts were
fully  amortized.

     During the six months ended December 31, 2006, the Company recognized a net
loss  of  $1,086,895  compared to a net loss of $1,033,254 during the six months
ended  December  31,  2005  ($543,923  and  $345,674  for the three months ended
December  31, 2006 and 2005, respectively).  The increase of $53,641, during the
six months ended December 31, 2006, is primarily attributable to the decrease of
$235,350 in interest expenses, offset by the increase of $105,739 in general and
administrative  expenses.

LIQUIDITY  AND  FINANCIAL  CONDITION

     During the six months ended December 31, 2006, the Company used $238,803 in
operating  activities.  Net  cash provided by financing activities was $476,000,
which  is  a  prepayment  on  a series of preferred stock the terms of which are
being  negotiated. Net cash used in investing activities was $387,118, which was
advanced  to  BioAgra  to  be  used  to  support its operations. The Company had
$42,438  of  cash and cash equivalents at December 31, 2006, which is being used
to  support  operations.  During  the  six  months  ended December 31, 2005, the
Company  used  $427,379  in  operating  activities.  During the six months ended
December  31, 2005, net cash provided by financing activities was $1,459,837; of
which  $2,070,500 was from the exercise of warrants, $200,000 were proceeds from
the prepayment on the sale of a preferred stock, $150,000 were proceeds from the
issuance  of  notes  payable and common stock and $960,663 was used to pay notes
payable.

     In  August  2005, the Company purchased a 50% equity interest in BioAgra (a
Georgia  limited  liability  company)  for  $905,000  cash  (which  includes the
$405,000  advanced to Xact Resources during the fiscal year ended June 30, 2005)
and a note payable of $595,000 which was paid in full in September 2005. BioAgra
is to manufacture and sell a beta glucan product, YBG-2000 marketed as AgriStim,
to  be  used  as  a  replacement  for hormone growth steroids and antibiotics in
animal  feed  products. BioAgra has completed the construction of its production
line,  and  during  the  six months ended December 31, 2006, BioAgra had limited
sales of its product. During the six months ended December 31, 2006, BioAgra has
been  working  with  potential customers on field testing trials of the AgriStim
product.

     As  of  December 31, 2006, if all existing outstanding warrants issued in a
January  2004  private placement were exercised, the Company will be required to
issue an additional 1,342,500 shares of common stock and would receive $192,125,
and  the Company, on a fully diluted basis (including the reservation of 832,029
shares  as  required  by the court in the Financing Agreement Litigation), would
have  29,995,271  shares  of  common  stock  issued  and  outstanding.

     However,  no  assurance  can  be  given  that any of these warrants will be
exercised.  If  the  warrants are exercised, the Company has decided that it may
use the additional funds received from the exercise of these warrants to support
the  operations  of  the  Company  and  its  investments.

     During the 2007 fiscal year, the Company intends to continue its efforts to
aid  BioAgra  with  the  continuing  development  of  its  sales, nationally and
internationally  in  other animal feed markets, such as the equine and the swine
markets.  In  addition,  in  January  2007  the  Company  signed  a  six-month


                                        2
<PAGE>
Technology Agreement to permit a prospective licensee the opportunity to conduct
a  market  survey  relating  to  its NCOS(TM) technology. We believe that if the
market  survey  is  favorable the Technology Agreement may mature into a royalty
paying  commercial  license  the  terms  and  conditions   of  which  are  under
negotiation  between  the  Company  and  the  perspective  licensee.

     The  Company intends to raise additional funds to support operations of the
Company  during  the  2007  fiscal year.  Such funds are to be raised through an
offering  of  a  preferred stock, the terms of which are in the process of being
finalized.

     To  the  extent  the  Company's  operations  are not sufficient to fund the
Company's  capital  requirements  the  Company  may  enter into a revolving loan
agreement  with  financial  institutions or attempt to raise capital through the
sale  of  additional  capital  stock  or  through  the issuance of debt.  At the
present  time  the  Company  does  not  have a revolving loan agreement with any
financial  institution nor can the Company provide any assurance that it will be
able  to  enter  into any such agreement in the future or be able to raise funds
through  the  further  issuance  of  debt  or  equity  in  the  Company.

RECENTLY  ISSUED  ACCOUNTING  STANDARDS:

     In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements".
This  statement  defines  fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures about
fair  value  measurements.  This  statement  applies  under  other  accounting
pronouncements  that require or permit fair value measurements.  SFAS No. 157 is
effective  for  the  Company for its fiscal year beginning on July 1, 2008.  The
Company is currently assessing the impact the adoption of SFAS No. 157 will have
on  its  consolidated  financial  statements.

     In  September  2006,  the  SEC issued SAB No. 108 in order to eliminate the
diversity  of  practice  surrounding  how  public  companies  quantify financial
statement misstatements.  In SAB 108, the SEC staff established an approach that
requires  quantification  of  financial  statement  misstatements  based  on the
effects  of  the misstatements on each of the Company's financial statements and
the  related  financial statement disclosures.  SAB No. 108 is effective for the
Company  for  its current fiscal year.  The adoption of SAB No. 108 did not have
an  impact  on  the  Company's  consolidated  financial  statements.

ITEM  3.     CONTROLS  AND  PROCEDURES

As  of  the  end  of the period covered by this Quarterly Report on Form 10-QSB,
the  Company  carried  out  an  evaluation,  under  the supervision and with the
participation  of  the  Company's  President and Chief Financial Officer, of the
effectiveness  of  the design and operation of the Company's disclosure controls
and  procedures  (as such term is defined in Rules 13a-14(c) and 15d-14(c) under
the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based upon
such  evaluation,  such  officers  have  concluded that the Company's disclosure
controls  and  procedures  are  effective as of the end of the period covered by
this  quarterly  report  on  Form 10-QSB in alerting them, on a timely basis, to
material  information  relating  to  the  Company required to be included in the
Company's  periodic  SEC  filings  and to ensure that information required to be
disclosed  in the Company's periodic SEC filings is accumulated and communicated
to  the  Company's  management,  including  its


                                        3
<PAGE>
President  and  Chief  Financial  Officer,  to  allow timely decisions regarding
required  disclosure.

There  was  no  change  to  the  Company's  internal  controls  over  financial
reporting during the fiscal quarter ended September 30, 2006 that has materially
affected,  or  is reasonably likely to materially affect, the Company's internal
controls  over  financial  reporting.




                          PART II - OTHER INFORMATION

ITEM  1.  LEGAL PROCEEDINGS - NO CHANGE.


                          PART II - OTHER INFORMATION

ITEM  2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS - NONE.

ITEM  3.  DEFAULTS  UPON  SENIOR  SECURITIES  -  NONE.

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITY  HOLDERS  -  NONE.

ITEM  5.  OTHER  INFORMATION  -  NONE.


                                        4
<PAGE>
ITEM  6.     EXHIBITS

     EXHIBITS.  The  following  is  a  complete  list  of exhibits filed as part
     of  this  Form  10-QSB.  Exhibit  numbers  correspond to the numbers in the
     Exhibit  Table  of  Item  601  of  Regulation  S-B.

          Exhibit 31.1  Certification  of  Chief  Executive  Officer pursuant to
                        Section  302  of  the  Sarbanes-Oxley  Act

          Exhibit 31.2  Certification  of  Chief  Financial  Officer pursuant to
                        Section  302  of  the  Sarbanes-Oxley  Act

          Exhibit 32.1  Certification  of  Principal  Executive  Officer
                        pursuant  to  Section  906  of  the  Sarbanes-Oxley  Act

          Exhibit 32.2  Certification  of  Principal  Financial  Officer
                        pursuant  to  Section  906  of  the  Sarbanes-Oxley  Act


                                        5
<PAGE>
                                   SIGNATURES

     In accordance with the requirements of the Securities Exchange Act of 1934,
the  registrant  has  duly  caused this report to be signed on its behalf by the
undersigned,  thereunto  duly  authorized.

                                             VYTA  CORP
                                             (REGISTRANT)

Date: February 20, 2007                 /s/ Paul H. Metzinger
                                        ----------------------------------------
                                        Paul H. Metzinger,
                                        President & CEO
                                        (Principle Executive Officer)


Date: February 20, 2007                 /s/ Kristi J. Kampmann
                                        ----------------------------------------
                                        Kristi J. Kampmann,
                                        Chief Financial Officer
                                        (Principle Financial Officer)


                                        6